TIDMNIPT
RNS Number : 2580I
Premaitha Health PLC
16 June 2017
Premaitha Health PLC
("Premaitha" or the "Company")
Premaitha launches Sage(TM) prenatal screening solution in Hong
Kong
Manchester, UK - 16 June 2017: Premaitha Health PLC (AIM: NIPT),
a leading international molecular diagnostics group focused on
non-invasive prenatal testing ("NIPT"), announces the launch of
Sage(TM), an NIPT solution incorporating additional prenatal
screening analysis tools.
Sage(TM) is an advanced NIPT analysis solution, available
through Yourgene Bioscience Singapore ("Yourgene"), which was
acquired by Premaitha in March 2017. It uses the latest technology
to detect placental DNA in a maternal blood sample, enabling
pregnant women to get fast, safe and reliable test results whilst
reducing the number of women required to undergo invasive follow up
tests with the associated risks.
Sage(TM) offers customers a cost-effective, high-quality and
flexible prenatal screening test that can be tailored to provide a
full clinical service for hospitals or to local laboratory set-ups,
all with a fast workflow of just three days. Utilising cloud-based
bioinformatics analysis, Sage(TM) allows laboratories to upload
sequencing data files to the cloud for remote analysis via
Yourgene's bespoke portal analysis package.
This solution will significantly expand Premaitha's addressable
market, giving access not only to new customers, but also offering
additional analysis tools for existing IONA(R) customers. Sage(TM)
is a complementary solution to IONA(R) as Premaitha's CE-marked
IONA(R) test detects trisomies 21, 18 and 13, whereas Sage(TM)
offers an extended test panel, including full chromosome analysis,
thereby enabling customers to maintain a competitive edge in the
growing number of laboratories offering NIPT.
Health authorities implementing public health screening policies
often mandate the use of a CE-marked test, such as IONA(R) test, or
equivalent. The launch of Sage(TM) will enable Premaitha to
capitalise on the growing awareness and demand for NIPT in
countries that have not yet seen the implementation of standard
regulation and for the private payer market in cases where public
provision is not available.
The Sage(TM) analysis solution has been developed utilising the
sequencing and bioinformatics expertise of Yourgene, alongside
Premaitha's clinical understanding, IVD and quality standards.
Sage(TM) is being launched at the Asian and Oceanic Obstetric
Congress of Obstetrics and Gynaecology in Hong Kong, where the
Company will be exhibiting and showcasing both the Sage(TM)
solution and the IONA(R) test.
Dr Stephen Little, CEO of Premaitha Health, commented: "To be
able to launch the Sage(TM) test, a valuable addition to the
Premaitha portfolio, having only completed the acquisition of
Yourgene three months ago, is a real testament to the capabilities
and expertise across our technical, clinical and commercial
teams.
"The launch of Sage(TM) presents a significant opportunity to
extend Premaitha's footprint and market penetration across Asia
Pacific and other regions. Yourgene already has a strong,
established network of customers across APAC and we are now in a
position to offer a complete NIPT solution to address the needs of
any laboratory, with our IONA(R) test continuing to service demand
for premium CE-IVD testing.
"Our team will work with local customers across the APAC region
to increase understanding of the benefits of NIPT and raise
awareness in and amongst clinicians. Premaitha is also very keen to
support healthcare professionals offering Sage(TM) and IONA(R) with
comprehensive clinical and technical training to ensure they are
well equipped to counsel pregnant women on their NIPT options."
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9700
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of placental DNA - and estimates the risk of a
fetus being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMGMVVKMGNZM
(END) Dow Jones Newswires
June 16, 2017 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024